Chronic myeloid leukemia
Conditions
Interventions
None listed
Sponsors
Jo Tatsuro
Novartis Pharma
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Chronic phase Chronic myeloid leukemia (CP-CML) patients during or after treatment with aciminib 2) Patients must be at least 18 years of age. 3) Patients whose written consent was obtained prior to enrollment 4) Patients who can provide sufficient quantities of stored samples for the study
Exclusion criteria
Exclusion criteria: (1) Patients with psychosis or psychiatric symptoms that would prevent the principal investigator or subinvestigator from participating in the study. (2) Patients who have a disease causing immunodeficiency or immunosuppression, or who are receiving immunosuppressive therapy. (3) Patients participating in other clinical trials at the time of enrollment. (4) Patients deemed inappropriate by the principal investigator or subinvestigator to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Changes in molecular response during asiminib treatment 2) Acquisition of memory cytotoxic T lymphocytes and their transition | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Transition in MR after discontinuation of asiminib. 2) Differences in immunological markers, such as memory CTL, between patients treated with asiminib and those with other tyrosine kinase inhibitors (historical controls). 3) Changes in CTL against CML-specific tumor antigens in patients with HLA-A*02:01 (02:06) or HLA-A*24:02. | — |
Contacts
Public ContactTatsuro Jo
Japanese Red Cross Nagasaki Genbaku Hospital
Outcome results
None listed